Home > Boards > US Listed > Biotechs >

Organovo Holdings, Inc. (ONVO)

Add ONVO Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 1/16/2018 12:47:00 PM - Followers: 311 - Board type: Free - Posts Today: 0


     Organovo is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications.
The company's NovoGen three-dimensional bioprinting technology is a platform that works across all tissue and cell types.
Organovo's NovoGen MMX Bioprinter was selected as one of the "Best Inventions of 2010" by TIME Magazine.
Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development.
Organovo's bioprinting technology can also be developed to create surgical tissues direct therapy.
Organovo leads the way in solving complex medical research problems and building the future of medicine.


ONVO Security Details Share Structure

Shares Outstanding 77,816,787 a/o Mar 16, 2014
Float 50,000,000 a/0 May24,2014
Authorized Shares 150,000,000 a/o May24, 2014

IR and Media Contacts:
Investor Relations Contact:
Media Contact:

Mailing Address:
Organovo, Inc.
6275 Nancy Ridge Drive, Suite 110
San Diego, CA 92121
Phone: 1-858-550-9994

For all the latest company information, details, news, please visit

Organovo's Scientific Founder and Chief Scientific Officer, Dr. Gabor Forgacs
is the Executive and Scientific Director of the Shipley Center for Innovation at Clarkson University and the George H. Vineyard Professor of Biological Physics at the University of Missouri.
He developed Organovo's breakthrough organ printing technology while leading a team of top regenerative medicine scientists from multiple universities, with the backing of a $5MM National Science Foundation Grant.
Professor Forgacs is the author of more than 150 peer reviewed journal articles and the textbook Biological Physics of the Developing Embryo, (with Stuart Newman), published by Cambridge University Press.
He holds a PhD in theoretical physics from the Roland Eotvos University, Budapest Hungary. He moved to the United States in the 1980's from the Institute of Physics of the French Atomic Energy Agency in Saclay to accept a professorship at Clarkson University. 
University of Missouri researcher doing groundbreaking work in regenerative medicine. Here is a video:


Organovo strives to advance regenerative medicine to new heights, by enabling bioprinting tissues and 3-D cellular constructs that were not possible before.
The novel and flexible capabilities of the bioprinting technology allow researchers to generate data faster and more efficiently, thus leading to cutting edge scientific findings, publications, and grants.

Organovo's 3-D NovoGen bioprinting technology allows for the placement of cells in any pattern desired.
First, small building blocks of any shape are created from the desired cell type.
Second, these pre-formed cell aggregates are loaded into a print cartridge that is then attached to the bio-printer.
The bioprinter deposits the cell aggregates one layer at a time, creating multiple stacked 2-D patterns.
A non-invasive gel is placed next to the cell aggregates to hold the desired 3-D shape as each layer is placed in 2-D.

After printing, the cell aggregates retain enough cellular mobility for them to flow into one another, creating a fused tissue construct.
The principles of developmental biology, including cellular self-assembly, allow the final construct to mature into the desired shape and properties.


World class support for NovoGen MMX

The NovoGen MMX Bioprinter™ is supported by our scientific and engineering team.
Every customer receives bioprinter training and access to Organovo's scaffold-free proprietary bioprinting process, which includes cell preparation to tissue maturation.
Additional consultation and application support are available upon request. Organovo's success comes from enabling our customers' success.  


NovoGen MMX Bioprinter

    The NovoGen MMX Bioprinter™ is a novel hardware and software platform at the forefront of bioprinting research and development. The NovoGen MMX™ was developed to meet challenges in biological research.
The platform takes primary or other human cells and shapes them into 3D tissue, with tremendous cellular viability and biology that is superior to even an animal model.
The platform is being used by Organovo's Pharma partners today to enable cutting edge research into drug discovery.

By allowing creation of three dimensional biological structures, Organovo creates functional human tissue that is superior to current disease models.
By enabling printing of tissue in a laboratory environment, investigations on the constructs can be integrated into your current analysis methods. (at 28 sec into the video is a full frontal view of the ONVO NovaGen MMX Bioprinter)

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ONVO News: Organovo Announces Release Date for Fiscal Third-Quarter 2018 Financial Results 01/18/2018 08:05:00 AM
ONVO News: Organovo Receives Orphan Designation From U.S. FDA for 3D Bioprinted Therapeutic Liver Tissue Treatment of Alpha-1 Antitrypsi... 12/26/2017 08:05:00 AM
ONVO News: Statement of Changes in Beneficial Ownership (4) 12/04/2017 09:01:36 AM
ONVO News: Current Report Filing (8-k) 12/01/2017 06:08:56 AM
ONVO News: Report: Developing Opportunities within Social Reality, The Finish Line, Facebook, Organovo, Plug Power, and Intrexon — Fut... 11/27/2017 08:20:00 AM
#10116   Total Revenue (TTM) RandolRocketman 01/16/18 12:47:00 PM
#10115   This company certainly has seen better days. Have RallyTheMarket 01/15/18 09:45:23 PM
#10114   More like DILI DILI.....sorry, bad pun pupuguru 12/31/17 10:28:43 AM
#10113   With the volume lately we may see sooner RandolRocketman 12/29/17 11:49:25 PM
#10112   Dilly dilly bettyfordallstar 12/28/17 05:24:50 PM
#10111   This ticker has been a target of (unlawful) RandolRocketman 12/28/17 04:31:26 PM
#10110   I won’t be in here too long since Sobber 12/27/17 06:33:44 PM
#10109   As disappointed as I am at the share bettyfordallstar 12/27/17 06:28:10 PM
#10108   To be fair Its not necessarily bad... if Sobber 12/27/17 04:54:07 PM
#10107   This is kind of a big deal. Not RandolRocketman 12/27/17 03:43:20 PM
#10106   Hopefully the stock can pull back some more Sobber 12/27/17 12:51:43 PM
#10105   Caused by what? CIMA7 12/27/17 01:12:43 AM
#10104   Not sure,Dec B numbers are not out yet bettyfordallstar 12/26/17 10:25:20 PM
#10103   How low they looking to cover in your opinion tonyjh 12/26/17 09:32:09 PM
#10102   I agree, 52wk low has been a solid bettyfordallstar 12/26/17 09:30:29 PM
#10101   I thought the same when I was watching tonyjh 12/26/17 08:42:11 PM
#10100   Short interest was 17% at the end of bettyfordallstar 12/26/17 05:54:35 PM
#10099   Looks like price suppression to me. tonyjh 12/26/17 05:10:09 PM
#10098   Crap price movement for such positive news. Very bettyfordallstar 12/26/17 04:12:42 PM
#10097   Organovo Receives Orphan Designation From U.S. FDA for Flanker100 12/26/17 01:26:50 PM
#10096   Hey Everyone, phytokaiser1 12/23/17 10:53:54 AM
#10095   Could see a bump on Tuesday to around batmen 12/23/17 06:19:07 AM
#10094   Very nice! It's been a while since we CIMA7 12/22/17 05:20:51 PM
#10093   Very good news indeed, thank you sir. Should bettyfordallstar 12/22/17 05:01:43 PM
#10092 etcetera 12/22/17 05:01:17 PM
#10091 It’s posted on FDA webs Tdogwm 12/22/17 04:58:25 PM
#10090   And what rumors would that be? bettyfordallstar 12/22/17 04:57:24 PM
#10089   Got some on FDA Rumors Tdogwm 12/22/17 03:26:43 PM
#10088   Thank you bettyfordallstar 12/17/17 12:45:18 AM
#10087   RE that large end of day trade: rongreen 12/16/17 11:31:25 PM
#10086   Thank you. Let's see a few more of those bettyfordallstar 12/16/17 11:02:22 PM
#10085   According to IH, there was a 2,313,083 share Alvie 12/16/17 09:58:26 PM
#10084   Does anyone have L2 ? There was a bettyfordallstar 12/15/17 08:26:47 PM
#10083   The FDA has reviewed more than 100 devices RandolRocketman 12/10/17 10:51:12 AM
#10082   The FDA has reviewed more than 100 devices RandolRocketman 12/10/17 10:51:10 AM
#10081   Did hear the ceo In conference call say bettyfordallstar 12/07/17 06:47:53 PM
#10080   I really bet you want to load up bettyfordallstar 12/07/17 06:45:04 PM
#10079   Looks like the former CEO still has a RandolRocketman 12/04/17 11:29:33 AM
#10078   I'm thinking more like Robocop. RandolRocketman 12/01/17 08:53:05 PM
#10077   I love this train of thought. Thanks for posting. rongreen 12/01/17 05:37:33 PM
#10076   Just what I thought of when I read 80857 12/01/17 04:51:08 PM
#10075   However long before that happens, I can see RandolRocketman 12/01/17 01:52:08 PM
#10074   Or terminator 80857 11/30/17 12:09:15 PM
#10073   Thats a great thought.. Bladerunner comes to mind TheMoneyTree 11/29/17 06:55:54 PM
#10072   I think many of us here share that perspective. morley480 11/29/17 01:42:02 PM
#10071   Interesting perspective. accrypto1 11/29/17 12:59:08 PM
#10070   I think smart money got into ONVO early RandolRocketman 11/28/17 11:57:18 PM
#10069   That's entirely possible. Still I think, with RandolRocketman 11/27/17 09:31:24 AM
#10068   Sure dump all your shares for fifty cents CIMA7 11/26/17 03:58:09 AM
#10067   Interesting end of the day spike bettyfordallstar 11/24/17 05:06:55 PM